JAZZ and PFE's sAML Combination Therapy Fails to Achieve EFS in Phase 2 Trial
Clinical Limitations of sAML Combination Therapy Exposed
In this Phase 2 clinical trial (UCHMC1913/NCT04231851), led by researchers at the University of California, Irvine (UCI), the combination therapy of Vyxeos (CPX-351) from Jazz Pharmaceuticals (JAZZ) and Daurismo (gladecitinib) from Pfizer (PFE) failed to achieve the 6-month event-free survival (EFS) target in high-risk acute myeloid leukemia (AML) patients. The researchers aimed to increase the 6-month EFS from the existing historical control group's 50% to 65%, but the actual clinical results were only 31% (95% confidence interval: 15-48%), failing to demonstrate efficacy. This indicates that improving the prognosis of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and therapy-related acute myeloid leukemia (t-AML) through the addition of targeted therapies remains challenging.
Mechanism of Action and Analysis of Unmet Expectations
Vyxeos is a cytotoxic anticancer drug that combines cytarabine and daunorubicin in a lipid nanoparticle with a 5:1 molar ratio, and Daurismo is an SMO inhibitor that targets leukemia stem cells by inhibiting the Hedgehog signaling pathway. The combination of these two drugs was theoretically expected to block stem cell-level resistance mechanisms and produce an anticancer synergistic effect, but in the actual patient group, it showed lower-than-expected survival. Among the 30 patients, 26 (86.7%) experienced severe adverse events (AEs) of grade 3-5, such as sepsis and febrile neutropenia, and the high toxicity of the combination therapy likely had a negative impact on survival improvement.
Subtle Hope Based on Detailed Data
Although the primary endpoint of 6-month EFS was not achieved, the overall response rate (ORR) was 51.7% (including 15 patients with complete remission and complete remission with incomplete hematological recovery), confirming encouraging tumor reduction effects. In particular, among the 15 patients who responded, 7 (46.7%) successfully transitioned to the allogeneic hematopoietic stem cell transplantation (alloHCT) stage, serving as a bridge to treatment. Additionally, in the TP53 gene mutation patient group, which has extremely poor prognosis and limited treatment options, significant survival signals were detected in inducing minimal residual disease (MRD) negativity, providing clues for the development of personalized therapies for specific genetic subtypes in the future.
Competitive Market and Future Prospects
The global acute myeloid leukemia (AML) treatment market is estimated at approximately $3.8 billion to $4.8 billion in 2026 and is expected to grow by more than 7% annually to nearly $6 billion by 2030. Currently, this market is dominated by AbbVie (ABBV) and Genentech's Venclexta (venetoclax) combination therapy as the standard of care (SoC), and fierce competition is unfolding with Daiichi Sankyo's Vanflyta (quizartinib) and other targeted pipeline drugs. The failure of this Phase 2 trial of Vyxeos and Daurismo has put a brake on the early expansion of indications for the two blockbuster drugs, but efforts to secure a niche market based on data on improved transplantation rates in high-risk patients are expected to continue.
This Phase 2 trial revealed that the combination therapy of Vyxeos and Daurismo achieved a 6-month EFS of only 31%, failing to reach the target of 65% and reducing expectations for commercialization. In the short term, this will disrupt the combination indication expansion strategy of Jazz Pharmaceuticals and Pfizer, and it will be more difficult to reverse the market share against AbbVie's Venclexta in the global AML treatment market of approximately $4 billion. However, the 51.7% ORR and high transplantation rate (46.7%) suggest that it can still be recognized as a meaningful bridging treatment strategy for high-risk patients. In the medium to long term, researchers will precisely analyze the mechanism of MRD negativity induction in patients with TP53 gene mutations, which will serve as an important milestone in the development of next-generation targeted leukemia stem cell pipeline drugs.
Source: ClinicalTrials.gov (api_ct)